An exosome-inspired docetaxel prodrug nanoplatform for potent STING activation and synergistic chemoimmunotherapy
Xinying Wang1, Xianlu Zhang2, Zixuan Jiao1
1Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Abstract:
The treatment of triple-negative breast cancer (TNBC) is significantly hampered by its immunosuppressive tumor microenvironment and limited T-cell infiltration. Activating the STING pathway presents a promising therapeutic avenue due to its potential to trigger a robust innate immune response and remodel the immunosuppressive landscape, thereby sensitizing tumors to immunotherapy. To harness this potential, we developed an exosome-mimetic nanoplatform (EMMDs). EMMDs is fabricated by co-loading a disulfide-linked docetaxel prodrug (DTX-SS-PA) and the STING agonist MSA-2 into polymeric micelles and further decorated with homotypic tumor cell-derived exosomal membrane (EM). This biomimetic design confers superior tumor-targeting capability. Upon reaching the tumor site, the prodrug is specifically activated to release cytotoxic docetaxel (DTX), while MSA-2 is concurrently released to potently activate the STING pathway. This dual action initiates a powerful antitumor immune response and reverses immunosuppression, leading to a synergistic chemo-immunotherapeutic outcome. In the murine TNBC model, EMMDs demonstrated remarkable antitumor efficacy, obviously provoking a robust STING-mediated type I interferon response and inhibiting tumor growth. This work presents a promising biomimetic strategy for remodeling the tumor immune microenvironment via efficient STING activation.
Insights
A novel nanoplatform activates the STING pathway to combat triple-negative breast cancer (TNBC). This approach enhances immune response and tumor suppression, offering a promising chemo-immunotherapy strategy for TNBC treatment.
Area of Science:
- Biomedical Engineering
- Immunology
- Oncology
Background:
- Triple-negative breast cancer (TNBC) presents treatment challenges due to its immunosuppressive tumor microenvironment and low T-cell infiltration.
- Activating the STING (Stimulator of Interferon Genes) pathway is a promising strategy to enhance innate immunity and sensitize tumors to immunotherapy.
Purpose of the Study:
- To develop an exosome-mimetic nanoplatform (EMMDs) for synergistic chemo-immunotherapy against TNBC.
- To investigate the potential of EMMDs to remodel the tumor immune microenvironment via STING activation.
Main Methods:
- Fabrication of EMMDs by co-loading a docetaxel prodrug (DTX-SS-PA) and STING agonist (MSA-2) into polymeric micelles, decorated with exosomal membranes.
- In vivo evaluation of EMMDs' antitumor efficacy and immune response modulation in a murine TNBC model.
Main Results:
- EMMDs demonstrated superior tumor targeting and synergistic release of docetaxel and MSA-2 at the tumor site.
- EMMDs effectively activated the STING pathway, inducing a robust type I interferon response and significant tumor growth inhibition.
- The nanoplatform successfully remodeled the immunosuppressive tumor microenvironment, leading to a potent chemo-immunotherapeutic outcome.
Conclusions:
- The developed exosome-mimetic nanoplatform (EMMDs) offers a promising strategy for dual drug delivery and STING pathway activation.
- EMMDs show significant potential for remodeling the tumor immune microenvironment and enhancing antitumor immunity in TNBC.
- This biomimetic approach represents a novel avenue for developing effective chemo-immunotherapies for challenging cancers like TNBC.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...